An 18-month course of the drug was shown to slow progression of the disease by 27 percent, compared to patients who were given a placebo.
This article, images and content belong to the source and curated for informational purposes.
Get the latest creative news from FooBar about art, design and business.
An 18-month course of the drug was shown to slow progression of the disease by 27 percent, compared to patients who were given a placebo.
This article, images and content belong to the source and curated for informational purposes.